Efficacy of cornstarch therapy in type III glycogen-storage disease

David A. Gremse, John C. Bucuvalas, William F. Balistreri

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


Type III glycogen-storage disease (GSD-III), due to decreased activity of the glycogen debranching enzyme amylo-1,6 glucosidase, may cause hepatic dysfunction, growth failure, and myopathy. The prevention of hypoglycemia by nocturnal intragastric formula infusion has been shown to enhance growth and improve the metabolic abnormalities associated with GSD-III. Cornstarch therapy was effective in preventing hypoglycemia in a few patients with GSD-III who were previously treated with nocturnal enterai formula infusion, but oral cornstarch had not been evaluated as an initial treatment. We studied three patients with GSD-III who exhibited growth failure, elevated serum aminotransferase concentrations, and asymptomatic hypoglycemia. Cornstarch therapy was associated with maintenance of normoglycemia, increased growth velocity, and decreased serum aminotransferase concentrations in all patients. Our experience suggests that cornstarch therapy can be effective as an initial treatment for patients with GSD-III.

Original languageEnglish
Pages (from-to)671-674
Number of pages4
JournalAmerican Journal of Clinical Nutrition
Issue number4
StatePublished - Oct 1990
Externally publishedYes


  • Cornstarch
  • Glycogen-storage disease
  • Growth velocity


Dive into the research topics of 'Efficacy of cornstarch therapy in type III glycogen-storage disease'. Together they form a unique fingerprint.

Cite this